QQ客服 官方微博 反馈留言

	Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial
	Zhou, Ai-Ping; Ma, Jianhui; Bai, Yuxian; Song, Yan; Li, Hangzhong; Xie, Xiaodong; Ren, Xiu-Bao; Ye, Dingwei; Liu, Jiyan; Luo, Hong
	2016
卷号	34期号:15
ISSN号	0732-183X
DOI	10.1200/JCO.2016.34.15_suppl.4565
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6384896
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhou, Ai-Ping,Ma, Jianhui,Bai, Yuxian,et al. Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial[J],2016,34(15).
APA	Zhou, Ai-Ping.,Ma, Jianhui.,Bai, Yuxian.,Song, Yan.,Li, Hangzhong.,...&Wang, Jinwan.(2016).Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.,34(15).
MLA	Zhou, Ai-Ping,et al."Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial".34.15(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。